BIIB : Analysis & Opinions

  1. Biogen and Siemens Healthineers Ink MS MRI Deal

    January 19, 2017
    The collaboration aims to develop MRI tools to treat multiple sclerosis.
  2. Biogen to Pay $1.25B to Forward Pharma in Patient Suit

    January 18, 2017
    Biogen will fork over $1.25 billion to Forward Pharma to settle a patent infringement case.
  3. New and Returning Bio-Tech Stock Picks for 2017

    January 17, 2017
    Biotech stocks had a rough year in 2016, overall. The new year has brought new optimism among some investors, but there are ...
  4. Biogen Says Spinraza Drug Did Well In Phase 3 Trial

    January 16, 2017
    Biogen said its spinal muscular atrophy drug Spinraza fared well in a Phase 3 study.
  5. Biogen Spinoff Bioverativ In Good Shape for Launch

    January 13, 2017
    Biogen's spinoff Bioverativ is on track to hit the market February 2, and its prospects are bright.
  6. Ionis Has High Hopes for Heart Drug Volanesorsen

    January 13, 2017
    Ionis plans to file an FDA application for its heart drug volanesorsen after it did well in studies.
  7. Drug Price Debate May Lead to Smaller Price Hikes

    January 5, 2017
    Some drug makers have capped drug price increases to single digits in 2017 amid public outcry.
  8. Biogen, Ionis Under Fire for Pricey Drug Spinraza

    January 4, 2017
    Biogen’s Spinraza was one of the last approved drugs of 2016, but its high cost raises eyebrows.
  9. Biogen Names Michel Vounatsos as New CEO

    December 20, 2016
    Prominent biotech company Biogen (NASDAQ: BIIB) has picked a new CEO from among its executive ranks. Michel Vounatsos, who ...
  10. Biogen Alzheimer's Drug Shows Promise in Study

    December 9, 2016
    Biogen’s beta amyloid targeting approach showed promise in an early-stage study.
  11. Biogen Spinoff Gets Gene Therapy Drugs (BIIB, SGMO)

    December 2, 2016
    Biogen’s spinoff Bioverativ remains on track for public listing in early 2017, and gets two key hemoglobinopathy programs ...
  12. Biogen MS Drug Sued for Patent Infringement (BIIB)

    December 2, 2016
    Biogen’s multiple sclerosis drug Tecfidera, which accounts for one-third of the company’s revenue, is up for a patent challenge.
  13. Is Lilly's Alzheimer's Fail Good for Biogen? (BIIB)

    November 24, 2016
    The failure of Eli Lilly's Alzheimer's drug study may or may not hurt rival drug makers that are developing similar dementia ...
  14. Shares of Eli Lilly Are Down 12% After Trial Miss (LLY, BIIB)

    November 23, 2016
    Eli Lilly & Co. reported that topline results for its phase III trial for Solanezumab, a monoclonal antibody, failed to meet ...
  15. Biotechs to Buy After Trump Victory (CELG, BIIB)

    November 10, 2016
    The Trump win eases political pressure on biotech and pharmaceuticals stocks, allowing them to end their long corrections.(CELG,BIIB,SGEB)
  16. Biogen, Ionis Gain on Spinraza News (BIIB, IONS)

    November 8, 2016
    Biogen and its drug partner Ionis reported positive data from a late-stage study of their drug Spinraza to treat childhood ...
  17. Biogen Posts 3Q Net of $1B on $3B Revenue (BIIB)

    October 26, 2016
    Biogen reported 3Q earnings of $1 billion, or $4.97 per share, on revenue of $2.96 billion. Biogen's adjusted 3Q EPS of $5.19 ...
  18. Does a Clinton Victory Scare the Biotech Sector? (AMGN, ILMN)

    October 13, 2016
    Biotech stocks face further turmoil if the Democrats win control of Congress and move to rein in prices for new drugs
  19. Biogen Gets Competition for SMA Therapy (BIIB)

    October 11, 2016
    The newly listed company can offer strong competition to Biogen and Ionis for SMA therapy.
  20. Anavex Jumps on Biogen Testing Deal (AVXL, BIIB)

    September 29, 2016
    The testing deal with Biogen is a significant step for Anavex.
  21. Biogen Submits NDA for SMA Drug (BIIB, IONS)

    September 28, 2016
    The company also plans to submit a Marketing Authorization Application to the European Medicines Agency to expedite commercialization ...
  22. Biogen Bets on Nusinersen (BIIB, IONS)

    September 22, 2016
    Biogen’s SMA drug nusinersen can emerge as a big winner in the mid- to long-term.
  23. Biogen Launches Flixabi To Raise Stakes In Biosimilar Wars (BIIB)

    September 9, 2016
    With biosimilars emerging as the new battleground for pharma, Biogen has launched its second anti-TNF against JNJ’s Remicade ...
  24. Top 10 Biotech Stocks for 2016 (ALXN, ALNY)

    August 30, 2016
    The biotechnology sector has many growth opportunities for the remainder of 2016. Here are the top ten biotech stocks, with ...
  25. 7 Quality Stocks That Don’t Pay a Dividend (PCLN)

    July 29, 2016
    These seven S&P 500 companies can afford to pay a dividend, but they prefer to invest in growth.
  26. Biogen Trounces Q2 Estimates; CEO to Retire Soon

    July 22, 2016
    Thursday was a busy and memorable day for Biogen (NASDAQ: BIIB): The noted biopharma released its latest set of quarterly ...
  27. FDA Approves Biogen and AbbVie's MS Treatment

    May 31, 2016
    A pair of prominent pharmaceutical companies, AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB), have gotten an important regulatory ...
  28. Why Biogen Is Hiving Off Its Hemophilia Business

    May 4, 2016
    Noted biotech Biogen is preparing a key divestment. The company revealed Tuesday that it will spin off its hemophilia business ...
  29. The 3 Largest Alpha-Seeking ETFs (PKW, PDP)

    May 1, 2016
    Learn the tactics of the three largest alpha-seeking ETFs, such as tracking share buybacks and and finding companies with ...
  30. The 3 Largest Health Care ETFs (XLV, IBB)

    April 25, 2016
    Find out which exchange-traded funds (ETFs) are the largest in terms of total assets under management (AUM) in the health ...
  31. (IBB) iShares NASDAQ Biotech SPDR ETF: Top 5 Holdings

    March 16, 2016
    Take a close look at the strong fundamentals underlying the top five holdings of the iShares NASDAQBiotechnology ETF as it ...
  32. Are These the Top Biotech Stocks of 2016?

    January 19, 2016
    These three biotech stocks are likely hold up better than their peers in 2016.
  33. The Top 10 Healthcare Stocks for 2016 (ABT, AGN)

    January 6, 2016
    Learn about the top 10 health care stocks expected to grow in 2016, with brief insights into each company's growth potential ...
  34. The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB)

    January 5, 2016
    Discover the top five biotechnology stocks for 2016. Learn each company's main revenue drivers and what factors cause their ...
  35. 3 Biotech Blue-Chip Companies to Keep an Eye On (AMGN, BIIB)

    December 23, 2015
    Discover three blue-chip biotech stocks you should keep your eye on in 2016. Despite recent struggles in the industry, these ...
  36. 6 Stocks to Own While the Fed Hikes Rates (PCLN, GOOG)

    October 14, 2015
    Understand what happens if the Federal Reserve increases interest rates. Learn about the top six stocks to own if the Fed ...
  37. Weakness In Biotech Will Likely Continue (XBI, IBB)

    October 1, 2015
    You can breathe easy with your biotech holdings--assuming you aren't counting on them to make you rich.
  38. Key Financial Ratios to Analyze Biotech Companies (AMGN, GILD)

    August 20, 2015
    Explore the rapidly growing biotechnology industry, and learn some of the key financial ratios investors use to analyze companies ...
  39. Top 3 Biotech ETFs (XBI, IBB)

    August 14, 2015
    Learn about three popular ETFs in the biotechnology sector, how they differ, and which ones may be appropriate for long term ...
  40. Does a Safe Biotechnology Stock Exist? (ISIS, BIIB)

    June 24, 2015
    Seasoned investors know that the biotechnology sector in inherently risky business.
  41. 3 Reasons That Biogen's Shares Could Rise (BIIB)

    June 16, 2015
    Biogen (NASDAQ: BIIB) is on a roll thanks to the fast growth of its multiple sclerosis drug Tecfidera, but this oral drug ...
  42. Biogen's Biosimilars Program Leaps Forward (BIIB)

    June 11, 2015
    Until recently, biologic drugs were insulated against generic competition because they are difficult to duplicate, and no ...
  43. How Does Biogen Make its Money?

    June 2, 2015
    Biogen is a healthy biotechnology company producing a stream of illness-fighting drugs. Its big sellers treat MS, and it ...
  44. 3 Things Biogen's Management Wants You to Know (BIIB)

    May 19, 2015
    Last month, Biogen (NASDAQ: BIIB), one of biotech's biggest companies, updated investors with its first-quarter financial ...
  45. Is This Biogen's Next Billion-Dollar Blockbuster? (BIIB)

    May 11, 2015
    Biogen (NASDAQ: BIIB) recently announced that its next-generation multiple sclerosis drug Zinbryta has been submitted for ...
  46. Young Investors: Should You Care About Dividends? (NFLX, PSXP)

    May 5, 2015
    If you're a young investor, you may want to consider a non-traditional approach to investing.
  47. Biogen's Tecfidera Loses Some Luster (BIIB, NVS)

    April 30, 2015
    Since winning FDA approval in 2013, Biogen's (NASDAQ: BIIB) Tecfidera has become the most widely prescribed oral multiple ...
  48. Why These May Be the Top 4 Growth Stocks of 2015

    April 17, 2015
    These four stocks have high upside potential in 2015.
  49. Biogen Earnings Preview: 3 Key Factors to Monitor (BIIB, LLY)

    April 14, 2015
    For the better part of a decade, Biogen (NASDAQ: BIIB) could simply do no wrong by its shareholders. Whereas the S&P ...
  50. Should Biogen Be Afraid of This Upstart? (BIIB, RCPT)

    April 13, 2015
    Biogen (NASDAQ: BIIB) is a biotech Goliath that is best known for its dominant leadership in the treatment of multiple sclerosis. ...
  51. Biogen Goes Generic (BIIB)

    April 9, 2015
    "If you can't beat 'em, join 'em" appears to be part of Biogen's (NASDAQ: BIIB) new mantra. Biogen's Rituxan is approved ...
  52. Can Biogen Change How We View Alzheimer's Disease? (BIIB)

    March 25, 2015
    As the global population gets increasingly older, Alzheimer's disease is going to get increasingly prevalent. As a result, ...
  53. Is It Time to Consider Selling Biogen? (BIIB)

    March 24, 2015
    Is it hot in here, or is it just Biogen (NASDAQ: BIIB)? Fresh off an official name change to "just" Biogen (from Biogen ...
  54. Is Biogen Worth Owning for the Long Haul? (BIIB)

    March 20, 2015
    Biogen Idec (NASDAQ: BIIB) is one of the planet's largest biotechnology companies and a key player in this industry that ...
  55. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  56. Adapt The 50-Day EMA To Enhance Your Trading

    January 14, 2015
    The 50-day EMA has numerous applications in price prediction, position choice & strategy building
  57. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  58. Four Breakout Stocks To Watch

    February 19, 2014
    These biotechnology and pharmaceutical stocks continue to put in new highs, but indicators are diverging.
  59. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  60. Rising Trend Channel Breakouts - Acceleration Or Top?

    July 4, 2012
    These stocks have been within rising trend channels, but recently have broken the trend channel to the upside. Such a breakout ...
  61. Can The Big Gains Continue Into 2012?

    January 3, 2012
    Learn the opportunities and risks that await some top performers in 2012.
  62. Biotech Stocks Ready Ready To Break Out

    September 7, 2010
    Biotech Stocks Ready Ready To Break Out